This is a notable improvement compared to many existing weight loss medications
People don't notice that, but if you listen to the story, they'll say, you know, ever since COVID-19, I'm working from home, so I don't have that walking commute I had every day
Restrictions continue to rise for many GIP and GLP-1 medications: In 2025, over 82% of people with insurance plans that offer coverage for Wegovy, Zepbound, and Saxenda will encounter restrictions, like prior authorization or step therapy, that make access difficult
History of Retatrutide Eli Lilly developed retatrutide as part of its efforts to advance next-generation therapies
[DOI] [PubMed] [Google Scholar] 120.Marsk R, Jonas E, Rasmussen F & Nslund E Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 19862006 in Sweden
These are all common and important considerations